Literature DB >> 33982582

Barriers in systemic delivery and preclinical testing of synthetic microRNAs in animal models: an experimental study on miR-215-5p mimic.

T Machackova1, P Vychytilova-Faltejskova, K Souckova, R Laga, L Androvič, G Mixová, O Slaby.   

Abstract

Mus musculus is the most commonly used animal model in microRNA research; however, little is known about the endogenous miRNome of the animals used in the miRNA-targeting preclinical studies with the human xenografts. In the presented study, we evaluated the NOD/SCID gamma mouse model for the preclinical study of systemic miR-215-5p substitution with a semitelechelic poly[N-(2-hydroxypropyl)-methacrylamide]-based carrier conjugated with miR-215-5p-mimic via a reductively degradable disulfide bond. Murine mmu-miR-215-5p and human hsa-miR-215-5p have a high homology of mature sequences with only one nucleotide substitution. Due to the high homology of hsa-miR-215-5p and mmu-hsa-miR-215-5p, a similar expression in human and NOD/SCID gamma mice was expected. Expression of mmu-miR-215 in murine organs did not indicate tissue-specific expression and was highly expressed in all examined tissues. All animals included in the study showed a significantly higher concentration of miR-215-5p in the blood plasma compared to human blood plasma, where miR-215-5p is on the verge of a reliable detection limit. However, circulating mmu-miR-215-5p did not enter the human xenograft tumors generated with colorectal cancer cell lines since the levels of miR-215-5p in control tumors remained notably lower compared to those originally transfected with miR-215-5p. Finally, the systemic administration of polymer-miR-215-5p-mimic conjugate to the tail vein did not increase miR-215-5p in NOD/SCID gamma mouse blood plasma, organs, and subcutaneous tumors. It was impossible to distinguish hsa-miR-215-5p and mmu-miR-215-5p in the murine blood and organs due to the high expression of endogenous mmu-miR-215-5p. In conclusion, the examination of endogenous tissue and circulating miRNome of an experimental animal model of choice might be necessary for future miRNA studies focused on the systemic delivery of miRNA-based drugs conducted in the animal models.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33982582      PMCID: PMC8820559          DOI: 10.33549/physiolres.934571

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  23 in total

1.  Prognostic significance of miR-215 in colon cancer.

Authors:  Mihriban Karaayvaz; Timothy Pal; Bo Song; Cecilia Zhang; Penelope Georgakopoulos; Saira Mehmood; Stephanie Burke; Kenneth Shroyer; Jingfang Ju
Journal:  Clin Colorectal Cancer       Date:  2011-07-12       Impact factor: 4.481

Review 2.  Tumor targeting via EPR: Strategies to enhance patient responses.

Authors:  Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2018-07-19       Impact factor: 15.470

3.  The long noncoding RNA PCAT-1 links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma.

Authors:  Yanli Ren; Jinhua Shang; Jinliang Li; Wenjuan Liu; Zhao Zhang; Jupeng Yuan; Ming Yang
Journal:  J Biol Chem       Date:  2017-09-08       Impact factor: 5.157

Review 4.  Animal Models to Study MicroRNA Function.

Authors:  Arpita S Pal; Andrea L Kasinski
Journal:  Adv Cancer Res       Date:  2017-08-08       Impact factor: 6.242

5.  MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion.

Authors:  Kandiah Jeyaseelan; Kai Ying Lim; Arunmozhiarasi Armugam
Journal:  Stroke       Date:  2008-02-07       Impact factor: 7.914

6.  MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in high-grade glioma.

Authors:  Yuzhen Wei; Jianjing Sun; Xingang Li
Journal:  Biotechnol Lett       Date:  2016-11-11       Impact factor: 2.716

7.  Mouse microRNA profiles determined with a new and sensitive cloning method.

Authors:  Shuji Takada; Eugene Berezikov; Yoshihiro Yamashita; Mariana Lagos-Quintana; Wigard P Kloosterman; Munehiro Enomoto; Hisashi Hatanaka; Shin-ichiro Fujiwara; Hideki Watanabe; Manabu Soda; Young Lim Choi; Ronald H A Plasterk; Edwin Cuppen; Hiroyuki Mano
Journal:  Nucleic Acids Res       Date:  2006-09-14       Impact factor: 16.971

Review 8.  The Potential for microRNA Therapeutics and Clinical Research.

Authors:  Johora Hanna; Gazi S Hossain; Jannet Kocerha
Journal:  Front Genet       Date:  2019-05-16       Impact factor: 4.599

Review 9.  Regulatory Mechanism of MicroRNA Expression in Cancer.

Authors:  Zainab Ali Syeda; Siu Semar Saratu' Langden; Choijamts Munkhzul; Mihye Lee; Su Jung Song
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

10.  miRNA-215-5p suppresses the aggressiveness of breast cancer cells by targeting Sox9.

Authors:  Jia Bao Gao; Ming Nan Zhu; Xiao Liang Zhu
Journal:  FEBS Open Bio       Date:  2019-10-22       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.